Pfizer Downgraded To Neutral From Outperform At Credit Suisse
July 20, 2017 at 11:07 AM EDT
Credit Suisse analyst Vamil Divan downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.